We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





Transgenic Mouse That Models Immune Disease’s Cytokine Storms Could Point to Treatment Solution for COVID-19

By HospiMedica International staff writers
Posted on 05 Jun 2020
Print article
Image: This is a microscopic photo of a blood smear from a transgenic mouse that mimics the human immune disorder, secondary HLH (Photo courtesy of Cincinnati Children’s Hospital Medical Center)
Image: This is a microscopic photo of a blood smear from a transgenic mouse that mimics the human immune disorder, secondary HLH (Photo courtesy of Cincinnati Children’s Hospital Medical Center)
A transgenic mouse developed at Cincinnati Children’s Hospital Medical Center (Cincinnati, OH, USA) to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) could play a key role in saving lives during the COVID-19 virus pandemic.

The so-called cytokine storm that inundates the bodies of severely ill COVID-19 patients with inflammatory cells produced by the immune system is a common feature of children battling secondary HLH, which happens in patients where initial HLH treatment has not worked. This common clinical feature of both illnesses was noticed by Gang Huang, PhD, one of the inventors of the genetically engineered mouse strain and a cancer pathologist at Cincinnati Children’s. He also noticed that severe COVID-19 disease clinical manifestations are very similar to those seen in transgenic laboratory mice created to faithfully mimic human secondary HLH in the lab. That preclinical laboratory research, some of it in collaboration with researchers in Wuhan, China, helped identify the drug ruxolitinib for treating secondary HLH. The anti-inflammatory drug is also used to treat other blood diseases, including leukemia.

During their work, Huang and researchers in China found other clinical studies involving other diseases where ruxolitinib also had worked well at quieting inflammation, and proceeded to successfully test the drug which dramatically reversed respiratory and multi-system inflammation in severely ill COVID-19 patients. A larger Phase III clinical trial RUXCOVID by Incyte and Novartis is now testing up to 400 severely ill COVID-19 patients with ruxolitinib, according to Huang, and preliminary clinical data from the study is expected during the summer.

“This is the first therapy we know of that appears to work effectively to quiet the cytokine storm and inflammation in severe COVID-19 disease, and there are no significant toxicities to patients who take the drug by two pills a day,” said Huang. “This is critical until we can develop and distribute enough effective vaccine to help prevent people from becoming infected.”

Related Links:
Cincinnati Children’s Hospital Medical Center

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Mattress
Powered Therapeutic Mattress
New
Digital Baby Scale
seca 354

Print article

Channels

Critical Care

view channel
Image: The injectable adhesive hydrogel for bone regeneration simultaneously induces cross-linking and mineralization with visible light (Photo courtesy of POSTECH)

Injectable Adhesive Hydrogel Uses Harmless Visible Light for Bone Regeneration

Bone defects, which can result from trauma, infections, or congenital conditions, are becoming increasingly prevalent, particularly in aging populations. Traditional treatments often involve bone grafts... Read more

Surgical Techniques

view channel
Image: Vibrational spectroscopy instrument (Photo courtesy of Mariam Al-Masmudi/CNIO)

‘Molecular Flashlight’ Detects Brain Metastasis Using Ultra-Thin Probe

One of the major challenges in biomedical research is the non-invasive monitoring of molecular changes in the brain caused by cancer and other neurological conditions. Now, a new experimental technique... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.